NEW ORLEANS, Dec. 27, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr., remind investors that they have until February 10, 2023 Lead Plaintiff’s motions in a securities class action lawsuit against Twist Bioscience Corporation TWSTif they acquired the Company’s shares between December 13, 2019 and November 14, 2022 inclusive (the “Class Period”). This lawsuit is pending in the United States District Court for the Northern District of California.

What you can do

If you have purchased Twist stock and would like to discuss your legal rights and how this case may affect you and your right to compensation for your economic loss, you can contact KSF Managing Partner Lewis Kahn toll-free at no cost to you at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-twst/ to learn more. If you wish to be a lead plaintiff in this class action lawsuit, you must file a petition with the court February 10, 2023.

About the lawsuit

Twist Bioscience and certain of its officers are alleged to have failed to disclose material information during the Class Period in violation of federal securities laws.

On November 15, 2022, Scorpion Capital reported that the company was “operating a Ponzi-like scheme that will end in bankruptcy,” that the company’s growth and revenue were unsustainable, and that the company exposed its fraud by misrepresenting capital expenditures continued and gross margins, among other topics.

As a result of this news, Twist Bioscience shares fell $7.57 per share, or nearly 20%, from a closing price of $38.00 per share on November 14, 2022 to $30.43 per share on November 15, 2022.

The case is Peters v. Twist Bioscience Corporation, et al. No. 22-cv-08168.

About Kahn Swick & Foti, LLC

KSF, which partners with former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s leading securities boutiques…